Seelos Therapeutics, Inc. Recorded Big Gain
Seelos Therapeutics, Inc. (SEEL:NASDAQ) jumped higher at $0.43, representing a gain of 59.5%. On Fri, Aug 16, 2024, SEEL:NASDAQ touched a New 2-Week High of $0.43. The stock appeared on our News Catalysts scanner on Mon, Aug 12, 2024 at 01:57 PM in the 'BIOTECH' category. From Fri, Aug 02, 2024, the stock recorded 30.00% Up Days and 18.18% Green Days
About Seelos Therapeutics, Inc. (SEEL:NASDAQ)
Apricus Biosciences Inc is engaged in the pharmaceutical industry. The company develops and commercializes products and product candidates in the areas of urology and rheumatology. Apricus' drug delivery technology is a permeation enhancer called NexACT. The company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon.
Top 10 Gainers:
- Cingulate Inc. (CING:NASDAQ), 268.54%
- Applied DNA Sciences, Inc. (APDN:NASDAQ), 78.22%
- Zoomcar Holdings Inc Com (ZCAR:NASDAQ), 60.27%
- Seelos Therapeutics, Inc. (SEEL:NASDAQ), 59.52%
- Virax Biolabs Group Limited (VRAX:NASDAQ), 53.24%
- Inspirato Inc Cl A (ISPO:NASDAQ), 40.69%
- Greenland Technologies Holding Corporation (GTEC:NASDAQ), 40.63%
- Vroom Inc. (VRM:NASDAQ), 34.83%
- Lumos Pharma, Inc. (LUMO:NASDAQ), 33.47%
- Yoshiharu Global Co. (YOSH:NASDAQ), 32.77%